Status:
RECRUITING
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Lead Sponsor:
Cure HHT
Collaborating Sponsors:
Augusta University
The Cleveland Clinic
Conditions:
Hereditary Hemorrhagic Telangiectasia
Arteriovenous Malformations
Eligibility:
All Genders
Brief Summary
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT). The purpose of this study is ...
Detailed Description
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is a research initiative led by the HHT Foundation International, Inc. ("Cure HHT"). The study focuses on Hereditary Hemorrhagic T...
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with HHT based on the Curacao diagnostic criteria or genetic testing.
- Able to provide informed consent or informed consent via a parent or legally authorized representative due to their age or medical condition.
Exclusion Criteria:
- Unable to provide informed consent or informed consent via a parent or legally authorized representative.
Key Trial Info
Start Date :
November 13 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2033
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT06259292
Start Date
November 13 2023
End Date
November 1 2033
Last Update
June 13 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
2
University of California, Los Angeles
Los Angeles, California, United States, 90095
3
University of California, San Francisco
San Francisco, California, United States, 94107
4
University of Colorado, Denver
Aurora, Colorado, United States, 80045